Pu Zhang

Pu Zhang

Auto-generated profile, based on publicly available information

Pu Zhang

Memorial Sloan Kettering Cancer Center 5

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2023 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
CSCaner Saygin
Caner Saygin
PZPu Zhang
Pu Zhang
JSJacob Stauber
Jacob Stauber
Ibrahim AldossIbrahim Aldoss
Ibrahim Aldoss
ASAdam S. Sperling
Adam S. Sperling
WSWendy Stock
Wendy Stock
Myeloid neoplasms arise from preexisting clonal hematopoiesis (CH); however, the role of CH in the pathogenesis of acute lymphoblastic leukemia (ALL) is unknown. We found that 18% of adult ALL cases harbored TP53, and 16% had myeloid CH-associated gene mutations. ALL with myeloid mutations (MyM) had distinct genetic and clinical characteristics, associated with inferior survival. By using single-cell proteogenomic analysis, we demonstrated that myeloid mutations were present years before the diagnosis of ALL, and a subset of these clones expanded over time to manifest as dominant clones in ALL. Single-cell RNA sequencing revealed upregulation of genes associated with cell survival and resistance to apoptosis in B-ALL with MyM, which responds better to newer immunotherapeutic approaches. These findings define ALL with MyM as a high-risk disease that can arise from antecedent CH and offer new mechanistic insights to develop better therapeutic and preventative strategies. Significance: CH is a precursor lesion for lymphoblastic leukemogenesis. ALL with MyM has distinct genetic and clinical characteristics, associated with adverse survival outcomes after chemotherapy. CH can precede ALL years before diagnosis, and ALL with MyM is enriched with activated T cells that respond to immunotherapies such as blinatumomab. See related commentary by Iacobucci, p. 142.

16 September 2022 in Science Advances
Verified
Journal Article
Open access
PZPu Zhang
Pu Zhang
LBLindsey T. Brinton
Lindsey T. Brinton
MGMehdi Gharghabi
Mehdi Gharghabi
SSSteven Sher
Steven Sher
KWKatie Williams
Katie Williams
RLRosa Lapalombella
Rosa Lapalombella
Using a genome-wide CRISPR screen, we identified CDK9 , DHODH , and PRMT5 as synthetic lethal partners with gilteritinib treatment in fms-like tyrosine kinase 3 ( FLT3 )–internal tandem duplication (ITD) acute myeloid leukemia (AML) and genetically and pharmacologically validated their roles in gilteritinib sensitivity. The presence of FLT3 -ITD is associated with an increase in anaerobic glycolysis, rendering leukemia cells highly sensitive to inhibition of glycolysis. Supportive of this, our data show the enrichment of single guide RNAs targeting 28 glycolysis-related genes upon gilteritinib treatment, suggesting that switching from glycolysis to oxidative phosphorylation (OXPHOS) may represent a metabolic adaption of AML in gilteritinib resistance. CDK9i/FLT3i, DHODHi/FLT3i, and PRMT5i/FLT3i pairs mechanistically converge on OXPHOS and purine biosynthesis blockade, implying that targeting the metabolic functions of these three genes and/or proteins may represent attractive strategies to sensitize AML to gilteritinib treatment. Our findings provide the basis for maximizing therapeutic impact of FLT3 -ITD inhibitors and a rationale for a clinical trial of these novel combinations.

12 August 2025 in Cancer Discovery
Verified
Journal Article
Closed access
PZPu Zhang
Pu Zhang
ZCZhendong Cao
Zhendong Cao
XPXiangyu Pan
Xiangyu Pan
YLYuqiao Liu
Yuqiao Liu
CCCynthia Castro
Cynthia Castro
JSJunwei Shi
Junwei Shi
GTPase-activating proteins (GAP) and guanine nucleotide exchange factors (GEF) play key roles in cancer development, but their large number and potential redundancy have limited systematic evaluation. In this study, we perform unbiased genetic screens to identify GAPs and GEFs with cancer- and lineage-specific requirements, as well as dual perturbation screens to dissect functionally relevant interactors of GAPs and GEFs. Application to primary specimens from patients with acute myeloid leukemia uncovers the GAP ARHGAP45 as a targetable dependency shared across cancers of hematopoietic origin while being dispensable in normal hematopoiesis. We demonstrate that targeting ARHGAP45-expressing cells can be achieved through T-cell receptor chimeric antigen receptor T cells directed at an ARHGAP45-encoded minor histocompatibility antigen and that pharmacologic targeting of CDC42 required upon ARHGAP45 depletion augments ARHGAP45-directed cell therapies. These studies provide a resource for probing oncogenic and druggable regulators of GTPases and strategies to target a GAP that represents a shared dependency across blood cancers. Significance: In this study, we systematically interrogated GAPs and GEFs in cancer and identified the GAP ARHGAP45 as a dependency shared across blood cancers while dispensable in normal hematopoiesis. Targeting ARHGAP45-expressing cells is achievable via T-cell receptor chimeric antigen receptor T cells directed at an ARHGAP45-derived antigen and small-molecule inhibition of GTPases required upon ARHGAP45 loss.

30 April 2026 in Cancer Discovery
Verified
Journal Article
Open access
TFTakeshi Fujino
Takeshi Fujino
JLJennifer Lewis
Jennifer Lewis
BCBingyi Chen
Bingyi Chen
TFTamar Y. Feinberg
Tamar Y. Feinberg
MMMaxim I. Maron
Maxim I. Maron
ADAnthony F. Daniyan
Anthony F. Daniyan
Developing chimeric antigen receptor (CAR) T cells for acute myeloid leukemia (AML) has been challenging due to a lack of known AML-associated antigens that spare normal hematopoietic precursor cells. Here we reasoned that donor autoantibodies from AML recipients cured following allogeneic transplant and responsible for graft-versus-leukemia effect could be engineered to create effective CAR-T cells. We generated CAR-T cells against one such antigen - U5 snRNP200, an RNA helicase localized to the AML cell surface and absent from normal hematopoietic precursors. Anti-U5 snRNP200 CAR-T cells were effective in human and syngeneic models of AML as well as B-cell acute lymphoblastic leukemia (B-ALL), a setting where surface U5 snRNP200 is also present. Armoring CAR-T cells with IL-18 led to antigen gain on AML, durable remission, and protection from AML rechallenge. These data thereby identify a CAR-T cell platform which addresses prior limitations in tumor-selectivity and safety for patients with acute leukemias.

1 May 2024
Verified
Other
Open access
PDF file
CSCaner Saygin
Caner Saygin
PZPu Zhang
Pu Zhang
JSJacob Stauber
Jacob Stauber
Ibrahim AldossIbrahim Aldoss
Ibrahim Aldoss
ASAdam S. Sperling
Adam S. Sperling
WSWendy Stock
Wendy Stock
Supplemental Figure 1. WHO/ICC subtypes for the B-ALL cohort.Supplemental Figure 2. Lymphoid clonal hematopoiesis (CH) mutations are less common in adults with ALL.Supplemental Figure 3. Blast percentage in the pre-treatment sample and detected variant allelic frequencies (VAF) of mutations in ALL patients with myeloid mutations.Supplemental Figure 4. Germline testing in the adult ALL cohort.Supplemental Figure 5. Associations of gene mutations and WHO/ICC disease subtypes in B-ALL.Supplemental Figure 6. Overall survival in adults with B-ALL.Supplemental Figure 7. Kaplan-Meier overall survival curves for Ph-negative B-ALL patients stratified based on the presence of TP53 and non-TP53 MyM (A), and treatment with different chemotherapy protocols (B, C, D). LH, low hypodiploidy.Supplemental Figure 8. T-lineage ALL with myeloid mutations (MyM).Supplemental Figure 9. Expression levels of lineage-specific surface markers.Supplemental Figure 10. Single cell DNA and protein sequencing to study the clonal architecture of Tlineage ALL with MyM.Supplemental Figure 11. A, Flow plots showing ETP-lymphoblast, myeloid, and mature lymphocytic compartments of ETP-ALL1, which were sorted for DNA extraction and sequencing. B, Distribution of variant allelic frequencies (VAFs) for myeloid (IDH2, DNMT3A) and NRAS mutations across subpopulations of cells in ETP-ALL1.Supplemental Figure 12. Clonal dynamics of ALL with MyM.Supplemental Figure 13. Two CH mutations (TP53 and DNMT3A) were detectable seven years before the diagnosis of therapy-related ALL22.Supplemental Figure 14. Clonal evolution of B-ALL2.Supplemental Figure 15. Lymphoblasts from B-ALL with MyM are characterized by their resistance to cytotoxic chemotherapy.Supplemental Figure 16. Curves showing viability of primary human B-ALL samples with TP53 mutation (n= 14), MyM (n= 16) and no MyM/TP53 (n= 24), treated with vincristine, doxorubicin, and blinatumomab at escalating doses.Supplemental Figure 17. Flow cytometry plots showing ALL22 (TP53-mutated B-ALL) sample treated with escalating doses of blinatumomab.Supplemental Figure 18. A, CR with MRD negativity rates in Ph-negative B-ALL patients treated with pediatric regimens, stratified based on age, gender, and treatment site. B, CR with MRD negativity rates in Ph-negative B-ALL patients treated with hyper-CVAD, stratified based on age, gender, and treatment site. C, CR with MRD negativity rates in Ph-negative B-ALL patients treated with inotuzumab.Supplemental Figure 19. A, MHC class I and II antigen expression in blasts from B-ALL with MyM vs B-ALL without MyM/TP53. B, Comparison of genes implicated in blinatumomab resistance in B-ALL with vs without MyM/TP53.

1 May 2024
Verified
Other
Open access
PDF file
CSCaner Saygin
Caner Saygin
PZPu Zhang
Pu Zhang
JSJacob Stauber
Jacob Stauber
Ibrahim AldossIbrahim Aldoss
Ibrahim Aldoss
ASAdam S. Sperling
Adam S. Sperling
WSWendy Stock
Wendy Stock
Supplemental Table 1. List of DNA gene mutations tested in diagnostic tumor samples of our ALL cohort.Supplemental Table 2. List of 80 genes with RNA sequencing coverage.Supplemental Table 3. Demographics of 400 adult ALL cases.Supplemental Table 4. List of first-line (initial) therapies in Ph-positive B-ALL, Ph-negative B-ALL, and Tlineage ALL patients.Supplemental Table 5. Baseline gene rearrangements and structural variants of 329 molecularly characterized adult B-ALL patients.Supplemental Table 6. Baseline gene rearrangements and structural variants of 71 molecularly characterized adult T-lineage ALL patients.Supplemental Table 7. List of pathogenic/likely pathogenic germline variants in our ALL cohort.Supplementary Table 8. Multivariable analysis of overall survival (OS) in B-ALL patients.Supplemental Table 9. Clinical characteristics of patients studied in scDNA + protein sequencing experiments.Supplemental Table 10. Clinical characteristics of patients studied in scRNA-seq experiment.Supplemental Table 11. Ingenuity pathway analysis comparing B-lymphoblasts from B-ALL with MyM vs B-ALL without MyM.